This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ptc Therapeutics, Inc.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Scott Joseph Brantley: Innovator in Deflazacort Therapy
Introduction
Scott Joseph Brantley is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of medicine, particularly in the treatment of Duchenne muscular dystrophy (DMD). His innovative approach to deflazacort therapy has garnered attention in the medical community.
Latest Patents
Scott Joseph Brantley holds a patent for "Methods of administering deflazacort therapy." This patent outlines a method of administering a fixed dose of deflazacort to subjects suffering from DMD. The therapy includes increasing the deflazacort dosage when the subject loses ambulation, as well as adjusting the dosage during concomitant administration of CYP3A4 inducers or inhibitors.
Career Highlights
Brantley is currently associated with PTC Therapeutics, Inc., where he continues to work on innovative therapies. His research focuses on improving treatment options for patients with DMD, showcasing his commitment to advancing medical science.
Collaborations
Some of his notable coworkers include Linda L Grasfeder and Stephen P Wanaski. Their collaborative efforts contribute to the ongoing research and development of effective therapies in the field.
Conclusion
Scott Joseph Brantley is a dedicated inventor whose work in deflazacort therapy represents a significant advancement in the treatment of Duchenne muscular dystrophy. His contributions are paving the way for improved patient outcomes and innovative medical solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile